Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Clinical pharmacology and therapeutics - 1 May 2011

Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt S W, Nikoloff D M, Hillman G, Fontecha M R, Lawrence H J, Parker B A, Wu A H B, Pierce J P

Abstract excerpt

We explored whether breast cancer outcomes are associated with endoxifen and other metabolites of tamoxifen and examined potential correlates of endoxifen concentration levels in serum including cytochrome P450 2D6 (CYP2D6) metabolizer phenotype and body mass index (BMI). Concentration levels of tamoxifen, endoxifen, 4-hydroxytamoxifen (4OH-tamoxifen), and N-desmethyltamoxifen (ND-tamoxifen) were measured from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Estrogen and related hormone effects

Share to Genotype

Share to Phenotype

Share to Tamoxifen

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 21430657
DOI: 10.1038/clpt.2011.32
PMCID: PMC3081375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.PMID 21430657Read ↗

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.Semantic proximity Read ↗

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.Semantic proximity Read ↗

A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients.Semantic proximity Read ↗

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.Semantic proximity Read ↗

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read ↗

Clinical and biomarker predictors of side effects from tamoxifen.Semantic proximity Read ↗

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast CancerSemantic proximity Read ↗

Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.Semantic proximity Read ↗

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.Semantic proximity Read ↗

Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency.Semantic proximity Read ↗

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.